
## BEST AVAILABLE COPY

## **FAX**



gsk GlaxoSmithKline

> GiaxoSmithKline PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

Tel: 919 483 2100 www.gsk.com

## Attached:

- 1. Transmittal Form with Certificate of Transmission by FAX
- 2. Terminal Disclaimer for 6.315.112
- 3. Terminal Disclaimer for 6,390,291
- 4. Response (2 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Signature Typed or printed name

TRANSMITTAL Filling Date First Named Inventor Art Unit  Art Unit  Total Number of Pages In This Submission  Fine Transmittal Form Pee Attached After Final After F	Doc Under the Paperwork Reduction Act of 1995, na pe	ersons are required	U.S. Patent and Yrader	PTO/SB/21 (09-04) roved for use through 07/31/2008, OMB 0651-0031 ment Office: U.S. DEPARTMENT OF COMMERCE tion unless it displays a valid OMB control number.	
FIRST Named Inventor Karl Andrew GARRILL Art Unit 3728  [tio be used for all correspondence effer Infilled Blung) Examiner Name FOSTER, Jimmy G.  Total Number of Pages In This Submission Altomay Docket Number PC4114  ENCLOSURES (Check all that apply)  ENCLOSURES (Check all that apply)  Fee Attached Licensing-related Pagers Appeal Communication to Board of Appeals and Interferences  Amendment / Reply Petition After Final Pedition to Convert to a Provisional Application Proprietary Information Orange of Correspondence Address  After Final Pedition to Convert to a Provisional Application Proprietary Information Orange of Correspondence Address  Terminal Discalamer Orange of Correspondence Address (Identify below):  Express Abandonment Request Response to Missing Parts Under Information Discalamer			Application Number	09/599,274	
First Named Inventor		L	Filing Date	06/22/2000	
(to be used for all correspondence efter initial filing)  Total Number of Pages in This Submission  ENCLOSURES (Check all that apply)  Fee Transmittal Form  Pee Attached  Anendment / Reply  After Attowance Communication to Board of Appeal Communication to Board of Appeals and Interferences of Appeals and	FORM		First Named Inventor	Karl Andrew GARRILL	
Total Number of Pages In This Submission  ENGLOSURES  (Check sil that apply)  Fee Transmittal Form  Pee Attached  Licenaing-related Papers  Petition  Amendment / Raply  After Final  Power of Attomay, Rayocauton  After Final  Provisional Application  After Final  Provisional Application  Application  Application  Application  Application  Applic			Art Unit	3728	
Fee Transmittal Form	(to be used for all correspondence after initi	lal filing)	Examiner Name	FOSTER, Jimmy G.	
Fee Transmittal Form    Drawing(s)	Total Number of Pages In This Submission		Altorney Docket Number	PG4114	
Fee Transmittal Form    Drawing(s)		ENCLOS	URES (Check all that apply	v)	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT  Firm Name GlaxoSmithKline  Signature Printed name Michael Strickland  Date Jone 10, 2005 Rag No. 47,115  CERTIFICATE OF TRANSMISSION/MAILING	Drawing(s)   1o TC     Appeal Communication to Board of Appeals and Interferences     Amendment / Reply   Petition   Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)     After Final   Provisional Application   Proprietary Information     Affidavits/declaration(s)   Power of Attorney, Revocation   Change of Correspondence Address   Status Letter     Extension of Time Request   Request for Refund   CD, Number of CD(s)     Information Disclosure Statement   Landscape Table on CD     Response to Missing Parts/ Incomplete Application   The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Ascount No. 07-1392.				
CERTIFICATE OF TRANSMISSION/MAILING	SIGNATURE ( Firm Name GlaxoSmithKline  Signature Frinted name Michael Strickland	A d			
CERTIFICATE OF TRANSMISSION/MAILING	Jone 10, 2005 Rag. No. 47,115				
	CERTI	FICATE OF	TRANSMISSION/MAILI	NG	

6/10/05 This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1490.

sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Date

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

John Jones